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Neurodegeneration (PKAN) is an autoso-
mal recessive disorder that is caused by
variation in pantothenate kinase-2 gene
(PANK2) gene on chromosome 20. The
common presentation of this disease
includes progressive dystonia,
Parkinsonism, retinopathy, cognitive
impairment, and spasticity. The typical
magnetic resonance imaging finding is eye
of the tiger sign in globus pallidus and not
pathogenic and not found in all patients. In
the present study, we describe two siblings
who have a novel variation of the PANK2
gene. These patients with the same geno-
type, have different ages at the onset of dis-
ease and also the various severity of the dis-
ease. The description of these cases helps to
understand this disease, its symptoms,
pathogenesis, and its treatment.
Introduction
Neurodegeneration with brain iron
accumulation (NBIA) includes a
heterogeneous group of hereditary
neurodegenerative diseases that occur with
symptoms such as dystonia, parkinsonism,
cognitive impairment and vision loss.1-3
The most common type is Pantothenate
Kinase-associated Neurodegeneration
(PKAN), due to a variation in the
pantothenate kinase-2 gene (PANK2) gene
on chromosome 20.4 The disease has two
types, classic and atypical, the classical type
occurs at an earlier age and more severe.
The typical MRI finding is eye of the tiger
sign that is T2-hypointensity surrounding a
central hyperintensity in globus pallidus
and not pathogenic and not found in all
patients.5-7 In this paper, we present two
siblings of patients with PKAN who have a
novel variation of the PANK2 gene.
Case Report
A 32-year-old woman (case 1) was
referred to our clinic because of gait
difficulties that had started at the age of
about 16 years. The family history, drug
history, and past medical history were
noncontributory. On neurologic
examination, the Mini-Mental State
Examination (MMSE) was normal. Cranial
nerve examination was normal and the
Ophthalmologic evaluation indicated no
evidence of visual impairment, Kayser-
Fleischer rings, pigmentary retinopathy and
atrophy of optic nerve. She had hypokinesia
and bradykinesia and limb rigidity, which
was more on the right side, also there were
generalized dystonia and spasticity of lower
limbs without cerebellar signs.
Acanthocytosis was not seen in the
peripheral blood smear and the other
laboratory tests were normal. A brain
magnetic resonance image (MRI) revealed
the eye of the tiger sign (Figure 1A), and the
genetic analysis showed a homozygous
variation in the PANK2 gene
NM_153638.3:c.706_708delGAA (GAA
deletion, p.E236 Del).
The second patient (case 2) was a 30-
year-old man presents with generalized
dystonia and Parkinsonism that had started
at the age of about 18 years. Gradually, the
dystonia increased in severity, His
developmental history was normal, the
ophthalmological examination was normal
with no evidence of visual impairment and
retinopathy. He also had a generalized
dystonia, hypokinesia, and limb rigidity.
There were no pyramidal or cerebellar
signs. Brain MRI discloses a typical eye-of-
the-tiger sign (Figure 1B), and a genetic
study detected a pathogenic variation in the
PANK2 gene (GAA deletion, p.E236 Del).
For DNA extraction from type of blood
cells, Q1AAMP DNA MICROKIT (Cat
number: 56304) was used. For
comprehensive investigation of all the
exons and splicing sites of the introns in
PANK2 gene, primers from another paper
were used (Table 1).8 Briefly, PCR reaction
was performed in a final volume of 25 µL
containing 100-200 ng of total DNA, 10
pmol of each primer, 2.5 mM MgCl2, 200
mM each of dNTP and 1 U Taq DNA
polymerase (Roche Diagnostics,
Mannheim, Germany). The reaction
mixture was cycled 35 times at 95◦C for 1
min, annealing temperature (°C) for 1 min
(refer to Table 1) and 72◦C for 1 min.
Electrophoresis of the PCR products was
performed on 2% agarose gels (Figure 2).
The PCR products were sequenced with the
forward or reversed primers on an ABI
3730XL sequencer (Macrogen Company,
Korea) and compared with control samples
using the FinchTV program and analyzed
on the NCBI website
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).Wit
h these methods, the target sequence for
each patient was compared with the normal
reference sequence, and mutations in the
exons and the splicing sites of the introns in
the PANK2 gene. All transcribed exons of
the PANK2 gene were investigated in
patients. delGAA homozygous mutation in
the exon2 was detected in both siblings and
their parent were heterozygous in this loca-
tion. Both patients were treated with
Madopar 125 three times daily and
Deferiprone 500 twice daily, which we did
not see any changes in symptoms after a
three month follow up.
We obtained the written informed
consent from the two patients for
publication of the case report
Discussion and Conclusions
Pantothenate Kinase-Associated
Neurodegeneration (PKAN) is an
autosomal recessive disorder caused by a
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variation in the PANK2 gene. The clinical
manifestations include speech disorder
Parkinsonism, dystonia, spasticity, Visual
loss, dysphagia seizure, and dementia.2,3,9
All of the patients with Pantothenate Kinase
Associated Neurodegeneration do not have
eye-of-the-tiger sign especially in the early
stages of this disease and all of the patients
with this sign do not have a PANK2
mutation.10-13 This gene has seven exons,
most variations are missense but
duplication, deletion and splice also
reported,6,14,15 in our patients, there is a
novel variation that was GAA deletion
resulting in the p.E236del that
bioinformatically or in silico showed it is
probably pathogenic mutation but needs
further investigation. Two of our patients
had manifestations but the progression, and
severity of the disease was different. The
course of the disease in the first patient was
faster and the symptoms were more severe. 
Case 2 had a later onset of symptoms,
about 18 years, with slow progression and
the severity of the symptoms was milder.
Usually Bulbar symptoms, generalized dys-
tonia, and gait disturbance, are more com-
mon in classical form and tremors, segmen-
tal dystonia, seizure, psychiatric disorders
and Parkinsonism more common in atypical
form of PKAN disease.4,16,17 Because the
precise mechanism of these diseases has not
been discovered so far, most of the treat-
ments used so far reduce the severity of
symptoms to some extent.1,18 The dystonia
is debilitating in these patients and is exac-
erbated over time and is treated with drugs
such as Oral and Intrathecal Baclofen,
Botulinum Toxin, gabapentin and anti-
cholinergics. Surgery such as Deep brain
stimulation, ablative pallidotomy or thalam-
otomy is also used to treat this disease.18-21
Iron chelator drugs such as deferiprone
have been used in some studies in neurode-
generative diseases and have promising
results. This drug passes through the blood-
brain barrier and reduces brain iron and
reduces the oxidative stress response in the
brain.21-24 In conclusion, although the dis-
ease is rare. But familiarity with clinical and
radiological symptoms can help to diagnose
this disease more easily.
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Table 1. Primers for studying the PANK2 gene by PCR-sequencing.
Primers                    Forward/Reverse                            Product size (bp)               TM(°C)
1                            F: GGAACTAGGCCGAGGGACAAAG                                       1200                                         63
                                  R:GAAGGTACCGCTTTCGGAG                                               
2                                  F: GCCCCAAAACCCTTTTGC                                              650                                          60
                              R: ACCACCTCTAGATGGCCAACTC                                            
3                                 F: TGGGTCTGTAGTAGCAGG                                             580                                          54
                                 R: CATTTGTTTGCATAATCCAG                                               
4                               F: GACATGGGCCCTGTGTTTTG                                           438                                          60
                                R: GGCCCGCCTGTATTTCTTAG                                              
5                                  F: GCTCTGTTTGAAGTTTGC                                              402                                          54
                                  R:ATGACTACATTTAGGCACTG                                               
6                             F: TCCTGTGACATTATCTAGCATG                                         429                                          54
                                   R: AGCCCATTTCACCTCCAC                                                 
7                                F:TCTGAAGTGCTTGGATAGTC                                            454                                          54
                                  R:CTTCCTGGTTGCTAATTTAG                                               
Figure 1. Brain magnetic resonance imaging T2-FLAIR images of case 1 (A) and 2 (B)
revealed the eye of the tiger sign.
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